Astellas decides not to pursue CV Therapeutics
This article was originally published in Scrip
Executive Summary
Astellas has decided not to raise its $16 per share bid for CV Therapeutics following Gilead Sciences agreed $20 per share offer. It will now withdraw its planned acquisition and the legal action related to it.